{"id":2695,"date":"2026-01-28T12:54:38","date_gmt":"2026-01-28T17:54:38","guid":{"rendered":"https:\/\/lifetein.com\/blog\/?p=2695"},"modified":"2026-01-28T12:54:39","modified_gmt":"2026-01-28T17:54:39","slug":"klh-should-my-peptide-be-conjugated-to-it","status":"publish","type":"post","link":"https:\/\/www.lifetein.com\/blog\/klh-should-my-peptide-be-conjugated-to-it\/","title":{"rendered":"KLH: Should My Peptide Be Conjugated To It?"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"798\" height=\"626\" src=\"https:\/\/lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH1.webp\" alt=\"KLH\" class=\"wp-image-2704\" srcset=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH1.webp 798w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH1-300x235.webp 300w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH1-768x602.webp 768w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH1-382x300.webp 382w\" sizes=\"(max-width: 798px) 100vw, 798px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Keyhole limpet hemocyanin (KLH)<\/strong>&nbsp;is a well-established cornerstone in the generation of peptide-specific antibodies. As a large, highly immunogenic carrier protein sourced from the marine mollusk&nbsp;<em>Megathura crenulata<\/em>, its primary function is to provide the necessary&nbsp;<strong>T-cell help<\/strong>&nbsp;that small, weakly immunogenic peptide antigens lack on their own<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3493659\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3457918\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. The covalent conjugation of your peptide to KLH is often the decisive step in transforming a simple sequence into a potent immunogen capable of eliciting a robust and high-titer antibody response. However, this strategy is not universally optimal; a successful outcome hinges on understanding the benefits, potential pitfalls, and key alternatives before proceeding.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h4 class=\"wp-block-heading\" id=\"key-takeaways\">Key Takeaways<\/h4>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KLH is a powerful immunogenic carrier<\/strong>&nbsp;that provides T-cell epitopes, essential for generating strong, class-switched antibody responses against small peptides<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3493659\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X0000195X\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n\n\n\n<li>The primary goal of conjugation is to&nbsp;<strong>enhance immunogenicity<\/strong>. Keyhole limpet hemocyanin has been demonstrated as an optimal carrier, significantly outperforming other proteins in eliciting peptide-specific antibodies in comparative studies<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X0000195X\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n\n\n\n<li>A significant drawback is the&nbsp;<strong>&#8220;carrier effect,&#8221;<\/strong>&nbsp;where the immune system can disproportionately target KLH-derived epitopes or terminal peptide &#8220;neo-epitopes,&#8221; potentially reducing the yield of antibodies against the core peptide of interest<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12730111\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.nature.com\/articles\/s41598-020-75754-7\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n\n\n\n<li><strong>Strategic peptide design<\/strong>&nbsp;is critical. LifeTein recommends targeting solvent-exposed, flexible regions (often C- or N-terminal), using sequences of 8-20 amino acids, and managing hydrophobicity for solubility<a href=\"https:\/\/www.lifetein.com\/peptide-antigen-design.html?srsltid=AfmBOoqtZFIWkkObUgodD0ZAXR5I1XNGcjMuBOyTks_WVEz4yIAdn0uZ\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/lifetein.com\/blog\/peptide-antigen-design\/?srsltid=AfmBOorUSP-SrD76Y8JwG99VM8qAlrq8deli0sSzDvGGktchKQjm707N\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n\n\n\n<li>A key alternative is the&nbsp;<strong>Multiple Antigenic Peptide (MAP)<\/strong>&nbsp;system, which uses a branched lysine core to present multiple peptide copies without a biological carrier, thereby avoiding anti-carrier antibodies and focusing the response on the peptide<a href=\"https:\/\/www.lifetein.com\/multiple-antigenic-peptides.html?srsltid=AfmBOop6FBkFU9KkRGvdf36KwY909CQkVaw7sUGFM38hog_sfOnlRM8G\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n<\/ul>\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-klh-and-why-is-it-used\">What is KLH and Why is it Used?<\/h2>\n\n\n<p class=\"wp-block-paragraph\">KLH is a high-molecular-weight, copper-containing glycoprotein renowned for its&nbsp;<strong>strong immunogenicity<\/strong>&nbsp;and low toxicity in animals and humans<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3493659\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. Its effectiveness stems from its size and complex structure, which are rich in foreign epitopes that can be recognized by helper T cells of the host immune system. Peptides, especially those shorter than 20 amino acids, are typically too small to be efficiently recognized by B cells and lack the necessary T-cell epitopes to stimulate a mature, high-affinity IgG response. By conjugating the peptide to Keyhole limpet hemocyanin, you effectively &#8220;piggyback&#8221; its presentation onto a protein that efficiently engages both arms of the adaptive immune system, leading to&nbsp;<strong>enhanced antibody titers<\/strong>&nbsp;and&nbsp;<strong>isotype maturation<\/strong>&nbsp;(e.g., increased IgG1)<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12730111\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X0000195X\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"the-compelling-benefits-of-klh-conjugation\">The Compelling Benefits of KLH Conjugation<\/h2>\n\n<h4 class=\"wp-block-heading\" id=\"superior-immunogenic-potency\">Superior Immunogenic Potency<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Extensive research validates KLH&#8217;s role as the benchmark carrier. A pivotal study comparing carrier proteins for cancer antigen vaccines concluded that the&nbsp;<strong>covalent attachment to KLH was optimal<\/strong>&nbsp;for inducing potent antibody responses<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X0000195X\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. Recent methodologies further leverage KLH&#8217;s potency by combining it with rational peptide sequence optimization, demonstrating that KLH-conjugated, engineered peptides elicit stronger antibody titers and improved affinity against native target sequences<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12730111\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOooKaOBognB4ltuO4oDZyTkOVEiQ6SdVy2ycY_4VVsNFajYgS2yM\" target=\"_blank\" rel=\"noopener\" title=\"\">Find more peptide conjugation here.<\/a><\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"proven-conjugation-chemistry\">Proven Conjugation Chemistry<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Reliable, kit-based methods exist for conjugating peptides to KLH. The two most common strategies are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Maleimide Chemistry<\/strong>: Used for peptides with a terminal cysteine residue. The thiol group of cysteine forms a stable thioether bond with a maleimide-activated KLH molecule<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n\n\n\n<li><strong>Carbodiimide (EDC) Chemistry<\/strong>: Used to conjugate peptides via carboxyl-to-amine crosslinking, typically targeting the N-terminus or lysine side chains of the peptide to lysines on KLH<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<br \/>These standardized protocols yield consistent conjugation efficiencies, allowing for predictable immunogen preparation<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"407\" src=\"https:\/\/lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2-1024x407.webp\" alt=\"KLH\" class=\"wp-image-2705\" srcset=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2-1024x407.webp 1024w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2-300x119.webp 300w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2-768x305.webp 768w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2-500x199.webp 500w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/01\/KLH2.webp 1066w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n<h2 class=\"wp-block-heading\" id=\"critical-considerations-and-potential-drawbacks\">Critical Considerations and Potential Drawbacks<\/h2>\n\n<h4 class=\"wp-block-heading\" id=\"the-carrierspecific-response-and-neoepitope-problem\">The Carrier-Specific Response and Neo-Epitope Problem<\/h4>\n\n\n<p class=\"wp-block-paragraph\">A major consideration is that the immune system will also generate a vigorous response against KLH itself<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3493659\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This &#8220;carrier effect&#8221; is not inherently problematic but must be accounted for in assay design. More importantly, research indicates that antibodies raised against peptide-KLH conjugates can be disproportionately directed against the&nbsp;<strong>terminal amino acids of the peptide<\/strong>&nbsp;(the linkage region), creating &#8220;neo-epitopes&#8221; not present in the native, full-length protein<a href=\"https:\/\/www.nature.com\/articles\/s41598-020-75754-7\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This can result in antisera with poor recognition of the target protein, as the most immunogenic part of the immunogen (the peptide terminus) is irrelevant to the final application.<\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"solubility-and-handling-challenges\">Solubility and Handling Challenges<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Keyhole limpet hemocyanin is notorious for its&nbsp;<strong>limited solubility<\/strong>, which can complicate conjugation and handling<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. While commercial formulations like PEGylated KLH improve solubility, this adds an extra layer of complexity<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. Furthermore, the large size of the KLH-peptide conjugate can sometimes cause&nbsp;<strong>steric hindrance<\/strong>, potentially masking the very epitope you aim to target, especially if it is internal rather than terminal<a href=\"https:\/\/www.lifetein.com\/multiple-antigenic-peptides.html?srsltid=AfmBOop6FBkFU9KkRGvdf36KwY909CQkVaw7sUGFM38hog_sfOnlRM8G\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"making-the-decision-a-framework-for-your-project\">Making the Decision: A Framework for Your Project<\/h2>\n\n\n<p class=\"wp-block-paragraph\">The choice to use KLH should be guided by your specific experimental goals and the nature of your peptide.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\"><strong>Factor<\/strong><\/th><th class=\"has-text-align-left\" data-align=\"left\"><strong>Favor KLH Conjugation<\/strong><\/th><th class=\"has-text-align-left\" data-align=\"left\"><strong>Consider Alternatives (e.g., MAPs)<\/strong><\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Goal<\/strong><\/td><td>Maximizing overall antibody titer for a challenging, small peptide.<\/td><td>Focusing the immune response exclusively on the peptide sequence; avoiding carrier interference.<\/td><\/tr><tr><td><strong>Peptide Nature<\/strong><\/td><td>Peptide is short (8-20 aa), linear, and has a terminal cysteine or lysine for clean conjugation<a href=\"https:\/\/www.lifetein.com\/peptide-antigen-design.html?srsltid=AfmBOoqtZFIWkkObUgodD0ZAXR5I1XNGcjMuBOyTks_WVEz4yIAdn0uZ\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/td><td>Peptide sequence is internal or poorly soluble; you require a defined, carrier-free immunogen.<\/td><\/tr><tr><td><strong>Antibody Use<\/strong><\/td><td>Subsequent assays (e.g., ELISA, WB) can be designed to minimize KLH interference.<\/td><td>You need antisera for direct cell surface staining or functional assays where anti-KLH antibodies could cause background.<\/td><\/tr><tr><td><strong>Technical Preference<\/strong><\/td><td>You prefer established, kit-based conjugation protocols.<\/td><td>You want direct control over the molar amount of peptide immunogen without a variable carrier protein<a href=\"https:\/\/www.lifetein.com\/multiple-antigenic-peptides.html?srsltid=AfmBOop6FBkFU9KkRGvdf36KwY909CQkVaw7sUGFM38hog_sfOnlRM8G\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n<h4 class=\"wp-block-heading\" id=\"the-multiple-antigenic-peptide-map-alternative\">The Multiple Antigenic Peptide (MAP) Alternative<\/h4>\n\n\n<p class=\"wp-block-paragraph\">A powerful alternative to carrier conjugation is the&nbsp;<strong>Multiple Antigenic Peptide (MAP)<\/strong>&nbsp;system. This involves synthesizing your peptide on a branched lysine core, creating a macromolecule where the peptide itself constitutes up to 95% of the mass<a href=\"https:\/\/www.lifetein.com\/multiple-antigenic-peptides.html?srsltid=AfmBOop6FBkFU9KkRGvdf36KwY909CQkVaw7sUGFM38hog_sfOnlRM8G\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. MAPs are intrinsically immunogenic due to their size and high epitope density, requiring&nbsp;<strong>no foreign carrier protein<\/strong>. This eliminates the anti-KLH response and focuses the immune system entirely on the peptide antigen, which can be advantageous for generating highly specific antibodies<a href=\"https:\/\/www.lifetein.com\/multiple-antigenic-peptides.html?srsltid=AfmBOop6FBkFU9KkRGvdf36KwY909CQkVaw7sUGFM38hog_sfOnlRM8G\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.lifetein.com\/peptide_synthesis_services.html?_gl=1*15bjc7l*_gcl_aw*R0NMLjE3NTIyNTk1NTEuQ2p3S0NBanc3TUxEQmhBdUVpd0FJZVhHSVpVMXFSOXh4MzJEX3d6U2NYYUx2aWhzLWYzMU1FZ3VOSDRhcW41NUJtZmM1RnN3MkdVR0tSb0NCS01RQXZEX0J3RQ..*_gcl_au*NzY2NTIxODguMTc1MTUyMjM4MQ..&amp;_ga=2.129734156.1835841867.1753856001-90406248.1735925224\" target=\"_blank\" rel=\"noreferrer noopener\">Find out more about peptide synthesis here.<\/a><\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions-faq\">Frequently Asked Questions (FAQ)<\/h2>\n\n<h4 class=\"wp-block-heading\" id=\"is-klh-safe-to-use-for-immunization\">Is KLH safe to use for immunization?<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Yes. KLH is widely used in both research and clinical settings due to its&nbsp;<strong>high immunogenicity and low toxicity<\/strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3493659\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. It has been employed in human cancer vaccine trials and as an immunomodulator for decades<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3457918\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"how-many-peptides-should-i-conjugate-to-each-klh-molecule\">How many peptides should I conjugate to each KLH molecule?<\/h4>\n\n\n<p class=\"wp-block-paragraph\">A high ratio is standard. Protocols often use a molar ratio of 80:1 (peptide:KLH) or similar to ensure the carrier surface is densely decorated with hapten, maximizing B-cell receptor engagement<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12730111\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. Commercial activation kits are optimized to provide a high number of conjugation sites per KLH molecule<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"can-i-use-something-other-than-klh-as-a-carrier\">Can I use something other than KLH as a carrier?<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Yes, other proteins like bovine serum albumin (BSA) or ovalbumin (OVA) are common. However, KLH is generally preferred for&nbsp;<strong>primary immunization<\/strong>&nbsp;due to its superior foreignness and immunogenicity. BSA or OVA are often used as coating antigens in assay development to avoid detecting anti-carrier antibodies from the serum<a href=\"https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/antibodies\/antibodies-learning-center\/antibodies-resource-library\/antibody-application-notes\/carrier-protein-activation-conjugation-data.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"where-can-i-get-help-designing-my-peptide-antigen-and-conjugation-strategy\">Where can I get help designing my peptide antigen and conjugation strategy?<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Specialized peptide service providers like&nbsp;<strong>LifeTein<\/strong>&nbsp;offer free bioinformatics tools and expert support for peptide antigen design, considering factors like solubility, hydrophilicity, and conjugation site selection to maximize your chances of success<a href=\"https:\/\/www.lifetein.com\/peptide-antigen-design.html?srsltid=AfmBOoqtZFIWkkObUgodD0ZAXR5I1XNGcjMuBOyTks_WVEz4yIAdn0uZ\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/lifetein.com\/blog\/peptide-antigen-design\/?srsltid=AfmBOorUSP-SrD76Y8JwG99VM8qAlrq8deli0sSzDvGGktchKQjm707N\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<br \/><br \/><\/p>\n\n\n<h4 class=\"wp-block-heading\" id=\"references\">References:<\/h4>\n\n\n<p class=\"wp-block-paragraph\">Chen, C.-H., Chiu, Y.-C., Huang, K.-Y., Huang, H.-H., Kuo, T.-W., Liu, Y.-C., Kao, H.-J., Yu, C.-L., Weng, S.-L., &amp; Liao, K.-W. (2025). A Reproducible Sequence-Level Strategy to Enhance Peptide Immunogenicity While Preserving Wild-Type Epitope Recognition. Antibodies, 14(4), 106. https:\/\/doi.org\/10.3390\/antib14040106<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aarntzen, E. H. J. G., de Vries, I. J. M., G\u00f6ertz, J. H., Beldhuis-Valkis, M., Brouwers, H. M. L. M., van de Rakt, M. W. M. M., van der Molen, R. G., Punt, C. J. A., Adema, G. J., Tacken, P. J., Joosten, I., &amp; Jacobs, J. F. M. (2012). Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 61(11), 2003\u20132011. https:\/\/doi.org\/10.1007\/s00262-012-1263-z<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kim, S. K., Ragupathi, G., Cappello, S., Kagan, E., &amp; Livingston, P. O. (2000). Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1\u2013KLH and GD3\u2013KLH conjugates. Vaccine, 19(4\u20135), 530\u2013537. https:\/\/doi.org\/10.1016\/s0264-410x(00)00195-x<br \/><br \/>Pon, R., Marcil, A., Chen, W., Gadoury, C., Williams, D., Chan, K., Zhou, H., Ponce, A., Paquet, E., Gurnani, K., Chattopadhyay, A., &amp; Zou, W. (2020). Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies. Scientific Reports, 10(1). https:\/\/doi.org\/10.1038\/s41598-020-75754-7<br \/><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Oyelaran, O., &amp; Gildersleeve, J. C. (2010). Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. PROTEOMICS \u2013 Clinical Applications, 4(3), 285\u2013294. https:\/\/doi.org\/10.1002\/prca.200900130<br \/><br \/><br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Keyhole limpet hemocyanin (KLH)&nbsp;is a well-established cornerstone in the generation of peptide-specific antibodies. As a large, highly immunogenic carrier protein sourced from the marine mollusk&nbsp;Megathura crenulata, its primary function is to provide the necessary&nbsp;T-cell help&nbsp;that small, weakly immunogenic peptide antigens &hellip; <a href=\"https:\/\/www.lifetein.com\/blog\/klh-should-my-peptide-be-conjugated-to-it\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":2704,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptide_synthesis"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=2695"}],"version-history":[{"count":4,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2695\/revisions"}],"predecessor-version":[{"id":2707,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2695\/revisions\/2707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media\/2704"}],"wp:attachment":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media?parent=2695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/categories?post=2695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/tags?post=2695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}